News

The merger, first announced in early December 2005, creates a late-stage company with two clinical stage compounds and a robust pipeline of preclinical candidates. In connection with the

The study will evaluate on an ongoing basis the ability of higher doses of Riquent to further reduce antibodies to double-stranded DNA (dsDNA). Antibodies to dsDNA are associated

Macugen (pegaptanib sodium injection) is a novel treatment for neovascular age-related macular degeneration (AMD). The drug was acquired by OSI late last year as part of its purchase

The results from the phase I portion of a phase I/II dose-escalation study of glufosfamide in combination with gemcitabine, marketed by Eli Lilly under the brand name Gemzar,

The mouse version of the drug, called 3G4, was effective at controlling the growth and spread of pancreatic cancer as a single agent and had significantly enhanced efficacy

Vitro has previously developed 29 adult pancreatic stem cell lines and has developed methodologies to induce differentiation of functional human beta cells from these cell lines. PhosphoSolutions makes

The results of the investigation demonstrate the safety and potential efficacy of Novagali’s treatment, called Nova22007, in patients suffering from Sjogren syndrome. This syndrome is a type of

If all shareholders of Berna tender their shares and the exchange offer is declared successful, Crucell will issue up to a maximum of 18,000,000 ordinary shares to the

Amplimexon is also currently in phase I/II clinical trials evaluating safety and efficacy in a number of cancers, including pancreatic, lung, breast, prostate, and multiple myeloma. The drug